Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsPriority Health Medicare Prior Auth Coverage | Ope…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Currentpriority healthPolicy 26328

    Priority Health Medicare Prior Authorization Criteria — Pharmacy & Specialty Drugs

    Customize your policy alerts

    Sign up for priority health Policy 26328 alerts

    Get alerted when Policy 26328 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Lists prior authorization, coverage, exclusion, and documentation requirements for many pharmacy and specialty drugs for Priority Health Medicare products and applies to providers requesting authorization for these drugs.

    Policy Summary
    Payerpriority health
    PolicyPrior Authorization Criteria — Pharmacy & Specialty Drugs
    Policy CodePolicy 26328
    Change TypeNo material changes
    Effective Date
    Next Review Date
    Key ActionPrescribers must provide documentation of prior therapies and responses; quantity limited to FDA-supported dosing and typical authorization durations of 1–2 years.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    Version 9document version
    ~80+products listed (this part)
    1-2 yrstypical auth duration
    manyrequires documentation
    commonspecialist prescriber often required

    Coverage Criteria and Product-Specific Conditions

    General coverage conditions

    Examples of covered indications when ALL of the following apply (general template used across many entries):

    General prior auth: Documentation of prior therapies and responses demonstrating inadequate response, intolerance, or FDA‑labeled contraindication; quantity limited to FDA‑approved dosing; duration per drug (commonly 1–2 years).

    Applies to many drug entries (see product-specific criteria).

    Amvuttra coverage — distinct initial and reauthorization criteria

    Amvuttra — distinct initial and reauthorization criteria

    HATTR‑PN initial: (1) Documentation of a pathogenic transthyretin (TTR) mutation AND (2) baseline polyneuropathy disability (PND) score ≤ IIIb AND (3) clinical signs/symptoms of neuropathy (e.g., motor disability, peripheral/autonomic neuropathy) AND (4) diagnosis confirmed by tissue biopsy, genetic testing, or radionuclide imaging.

    Not approved for primary (light‑chain) amyloidosis; initial coverage one year.

    Policy Summary
    Payerpriority health
    PolicyPrior Authorization Criteria — Pharmacy & Specialty Drugs
    Policy CodePolicy 26328
    Change TypeNo material changes
    Effective Date
    Next Review Date
    Key ActionPrescribers must provide documentation of prior therapies and responses; quantity limited to FDA-supported dosing and typical authorization durations of 1–2 years.
    SourceLink
    On This Page
    Coverage Criteria and Product-Specific ConditionsCoding, Laboratory Thresholds, and Numeric CriteriaPrior Authorization, Documentation, and Denial RisksStep Therapy Requirements and TablesQuantity Limits and Dosing ConstraintsSite-of-Care and Prescriber Specialty RequirementsBiosimilar Substitution and DocumentationPolicy Background and ScopeKey Definitions and Clinical ThresholdsInitial Therapy Criteria and RequirementsReauthorization and Continuation Criteria
    ATTR‑CM initial: (1) Trial and failure or intolerance to tafamidis (or contraindication) AND (2) NYHA class I–III heart failure with clinical manifestations or prior HF hospitalization AND (3) ECHO or CMR demonstrating cardiac involvement (increased LV wall thickness) AND (4) diagnosis confirmed by tissue biopsy, genetic testing, or radionuclide imaging; if radionuclide imaging used, require Grade 2–3 cardiac uptake.

    Initial coverage one year; reauthorization requires documented clinical benefit.

    Reauthorization: Documentation demonstrating positive clinical response compared to baseline (examples: improved neuropathy symptoms, improved function, reduced cardiovascular hospitalizations or improved quality of life).

    Reauthorization one year where specified.

    Arikayce coverage — MAC lung disease criteria

    Arikayce — MAC lung disease criteria

    Initial: Sputum culture supporting Mycobacterium avium complex (MAC) lung disease diagnosis AND documentation of failure to obtain negative sputum cultures after a minimum of 6 months of a multidrug background regimen.≥6 months

    Prescribed by or in consultation with infectious disease specialist or pulmonologist; initial approval 6 months; reauthorization requires recent negative sputum culture within 30 days.

    Benlysta coverage — SLE and lupus nephritis criteria

    Benlysta — SLE and lupus nephritis criteria

    SLE initial: SELENA‑SLEDAI score ≥6 AND either anti‑dsDNA >30 IU/mL or ANA >1:80 AND patient is taking two of the following together for ≥12 weeks: a steroid, an immunosuppressant, and/or hydroxychloroquine.SELENA‑SLEDAI ≥6

    Prescriber must be a specialist or consult one; initial coverage 1 year; reauth 2 years.

    Lupus nephritis (LN) initial: Confirmed diagnosis of SLE AND kidney biopsy confirming class 3, 4, and/or 5 disease AND receiving standard therapy for LN (e.g., mycophenolate or azathioprine plus steroid).

    Reauthorization requires evidence of clinical improvement including improved or stable eGFR.

    BRAFTOVI - Covered with criteria

    Examples of product-specific required conditions

    BRAFTOVI requirements: Patient must have documentation of BRAF V600 mutation status.

    Coverage duration two years.

    Briviact - Covered with criteria

    BRIVIACT requirements: Documentation of trial and failure with generic levetiracetam and at least one other generic anticonvulsant for the treated seizure condition.

    Coverage duration two years.

    Calcipotriene-betamethasone - Covered with criteria

    Calcipotriene‑betamethasone scalp suspension: Documentation of trial and failure with a generic topical steroid for the scalp in combination with generic calcipotriene solution; failure defined as inadequate response.

    Coverage duration two years.

    Colistimethate - Covered with criteria

    Colistimethate use: Covered only when administered intravenously (IV) or intramuscularly (IM) with documentation that infection is proven or strongly suspected due to susceptible bacteria by culture/susceptibility or local epidemiology; nebulized/inhalation administration is not covered.

    Prescriber should be or consult an infectious disease specialist; coverage duration one year.

    Cosentyx - Covered with criteria

    Cosentyx requirements: Must not be used in combination with other biologic drugs, Otezla, or JAK inhibitors. Documentation of prior therapies and responses required; prescriber is a specialist or has consulted a specialist. Specific prior therapy trials required per indication (e.g., NSAID for ankylosing spondylitis; traditional non‑biologic immunomodulator for psoriasis).

    Coverage duration two years; dosing per FDA label or compendia.

    Dupixent - Indication-specific criteria

    Dupixent — multiple indication-specific criteria

    Asthma initial coverage: Oral corticosteroid‑dependent asthma OR eosinophilic phenotype (blood eosinophils ≥150 cells/µL at initiation OR ≥300 cells/µL in prior 12 months) AND prior failure of 1 ICS/LABA in past 6 months (≥4 weeks on therapy).eosinophils ≥150 or ≥300 per stated windows

    Reauthorization requires documented clinical benefit.

    Eosinophilic esophagitis (EoE) initial coverage: Esophageal biopsy with ≥15 eosinophils per high power field (HPF), weight ≥15 kg, symptoms of esophageal dysfunction, AND trial and failure of a PPI or swallowed topical steroid for ≥2 months.>=15 eos/HPF

    Reauthorization requires reduction in eosinophil count or symptoms.

    Chronic urticaria initial coverage: Urticaria >6 weeks AND trial and failure of one H1 antihistamine.>6 weeks

    Reauthorization requires documentation of clinical benefit.

    Bullous pemphigoid initial coverage: Trial and failure of oral or high‑potency topical steroid AND trial and failure of one steroid‑sparing agent (doxycycline, methotrexate, mycophenolate, or azathioprine).

    Reauthorization requires reduction in blistering and itching.

    Ebglyss - Covered with criteria

    Ebglyss — atopic dermatitis requirements

    Ebglyss initial coverage: Confirmation of moderate to severe atopic dermatitis AND trial and failure of Rinvoq AND trial and failure of Dupixent.

    Initial limited dosing schedule (4 doses first month then maintenance) and prescriber specialist required.

    Ebglyss reauthorization: Positive clinical response compared to baseline AND patient on maintenance dosing (every 4 weeks) or every 2 weeks if inadequate response to 4‑week dosing.

    Initial 1 year (limited doses); reauth 2 years.

    Chronic urticaria initial therapy

    Chronic urticaria — Initial coverage

    Chronic urticaria initial: Confirmed diagnosis of urticaria occurring for more than 6 weeks AND trial and failure of one H1 antihistamine.

    Chronic urticaria reauthorization

    Chronic urticaria — Reauthorization

    Chronic urticaria reauth: Documentation of clinical benefit compared to baseline (e.g., improved symptoms).

    Bullous pemphigoid initial therapy

    Bullous pemphigoid — Initial coverage

    Bullous pemphigoid initial: Diagnosis of bullous pemphigoid AND trial and failure with oral or high‑potency topical steroid AND trial and failure with one steroid‑sparing agent (doxycycline, methotrexate, mycophenolate, or azathioprine).

    Bullous pemphigoid reauthorization

    Bullous pemphigoid — Reauthorization

    Bullous pemphigoid reauth: Documentation supporting reduction in blister formation and itching with therapy (clinical improvement vs baseline).

    Eltrombopag ITP criteria

    Eltrombopag — ITP initial requests

    Platelet threshold: Platelet count <30,000/mcL OR <50,000/mcL with bleeding or bleeding risk factors (e.g., history of bleeding, anticoagulation, peptic ulcer disease, falls).
    Prior therapy failures: Inadequate response or intolerance to steroids or IVIG AND inadequate response or intolerance to rituximab or splenectomy.
    Concomitant therapy restriction: Must not be used in combination with other maintenance ITP drugs including other thrombopoietin receptor agonists.

    Reauthorization: current platelet count and evidence of response required.

    Fasenra initial criteria

    Fasenra — severe eosinophilic asthma initial

    Eosinophil count: Blood eosinophil ≥150 cells/µL within 6 weeks OR ≥300 cells/µL in the previous 12 months.

    Provide documented count; prescriber specialist; reauthorization requires clinical benefit.

    Prior therapy failure: Trial with failure of 1 ICS/LABA inhaler in past 6 months (failure = inability to improve on therapy for ≥4 weeks).

    Evrysdi criteria

    Evrysdi — spinal muscular atrophy

    Diagnostic confirmation: Genetic testing confirming diagnosis of spinal muscular atrophy (SMA).

    Prescriber neurologist or consultation required; patient must not be receiving Spinraza or planning/received gene therapy (Zolgensma).

    Concurrent therapy restriction: Not eligible if receiving nusinersen (Spinraza) or if patient has received or plans to receive gene therapy for SMA.

    Initial and reauthorization coverage duration: 12 months.

    Eucrisa initial criteria

    Eucrisa — topical therapy prerequisite

    Topical steroid trial: Trial and failure of a prescription‑strength topical steroid for the current condition OR if steroid inappropriate, trial and failure of a generic topical calcineurin inhibitor.

    Prescriber documentation required.

    Enbrel criteria

    Enbrel (and Enbrel Mini) — rheumatoid and other indications

    Prior non‑biologic trial for RA/psoriasis: Trial and failure of one traditional non‑biologic immunomodulator (e.g., methotrexate) for RA and psoriasis; for ankylosing spondylitis try and fail one NSAID.

    Dosing per FDA label; prescriber specialist or consultation required.

    Prescriber restriction: Prescriber is a specialist or has consulted with a specialist for the condition being treated.
    Combination exclusion: Must not be used in combination with other biologic drugs, Otezla, or JAK inhibitors.

    Evrysdi duration

    Evrysdi coverage duration

    Duration: Initial authorization 12 months; reauthorization 12 months.

    Reauthorization requires documentation of positive clinical response compared to baseline.

    Endari criteria

    Endari — sickle cell disease

    Hydroxyurea prerequisite: Patient must have tried and failed hydroxyurea (failure = continued pain episodes despite appropriate dosing or intolerance).

    Prescriber documentation required.

    Evenity criteria

    Evenity — osteoporosis

    Prior therapies or high fracture risk: Either trial/failure/intolerance to oral bisphosphonates AND either zoledronic acid or Prolia, OR very high fracture risk defined by T‑score ≤ −3.0 OR ≤ −2.5 with fragility fracture or history of severe/multiple fragility fractures.

    Cumulative use >12 months not covered.

    GATTEX criteria

    GATTEX — short bowel syndrome

    Parenteral dependence: Documentation of dependence on parenteral support defined as inability to be weaned from parenteral nutrition.

    Reauthorization requires sustained decrease in parenteral support volume from baseline.

    Growth hormone therapy criteria

    Growth hormone products — children and adults

    Children GH criteria: Untreated growth velocity curve ≥1 year showing growth velocity <10th percentile for bone age and sex; open growth plates; bone age ≥1 year behind chronological age (exceptions apply); documented GH deficiency via two stimulation tests with peak <10 ng/mL or peak <15 ng/mL plus low IGF‑1/IGFBP‑3.

    Must be prescribed by an endocrinologist, gastroenterologist, or nephrologist; authorization one year.

    Adults GH criteria: Confirmation of GHD by suboptimal GH‑stimulation test OR persistent childhood‑onset GHD OR documented pituitary/hypothalamic disease with ≥3 pituitary hormone deficiencies and low IGF‑1.

    Growth hormone: initial therapy

    Growth hormone products — coverage criteria (children and adults)

    Pediatric GHD initial criteria: Submit untreated growth velocity curve ≥1 year showing growth velocity <10th percentile for bone age and sex; open growth plates; bone age ≥1 year behind chronological age (unless exception); documented GH deficiency via two stimulation tests with peak <10 ng/mL or peak <15 ng/mL plus low IGF‑1/IGFBP‑3.

    Prescriber: endocrinologist/gastroenterologist/nephrologist; duration one year.

    Adult GHD confirmation options: Adults must have confirmation by: (1) suboptimal GH‑stimulation test; OR (2) persistent childhood‑onset GHD; OR (3) pituitary/hypothalamic disease plus ≥3 pituitary hormone deficiencies and low IGF‑1.

    HAE therapies

    Hereditary angioedema (HAE) therapies — coverage conditions

    Haegarda initial: Patient age ≥6 years; prescriber is allergist/immunologist/hematologist or HAE specialist; submit C4, C1‑INH protein, and C1‑INH function labs confirming diagnosis; not used concurrently with ACE inhibitor or other preventative HAE therapies; not for acute attack treatment.

    Authorization duration: 1 year; reauth requires decreased frequency of attacks.

    Icatibant‑like product: Patient age ≥18; specialist prescriber; submit C4, C1‑INH protein and function labs; concurrent ACE inhibitor use not covered; reauth requires documentation of favorable clinical response and prior approved syringe use.

    Authorization duration: 6 months.

    Biologics: immunomodulator criteria

    Biologic immunomodulators (e.g., adalimumab, related products) — coverage criteria

    Prior therapy requirement: For rheumatologic/immune indications (RA, psoriasis, ankylosing spondylitis, hidradenitis suppurativa, uveitis, JIA) must try and fail one traditional non‑biologic immunomodulator or appropriate first‑line agent (e.g., NSAID for AS) unless exceptions apply.

    Failure defined as intolerance or inability to improve symptoms.

    Dosing and documentation: Dosing must follow FDA labeling or be supported in approved compendia. For shortened‑interval dosing in Crohn's/UC provide two of: symptoms, imaging showing active disease, fecal calprotectin >120, CRP ≥300, plus inadequate trough levels and initial response to therapy.

    Authorization duration commonly two years.

    Prescriber requirement: Prescriber is a specialist or has consulted with a specialist for the condition being treated.

    IVIG: documentation and limitations

    Intravenous immunoglobulin (IVIG) — coverage limitations

    Documentation for IVIG: Submit current weight and requested dose; dosing must follow FDA labeling or accepted standards; weight‑adjust dose if BMI ≥30 or actual body weight ≥20% above ideal; provide medical records supporting diagnosis and dosing.

    For myasthenia gravis: coverage limited to acute myasthenic crisis with decompensation; chronic or routine use not covered.

    Kerendia: coverage criteria

    Kerendia (finerenone) — initial treatment constraints

    Kerendia for HF (EF ≥40%): NYHA class II–IV with documented EF ≥40% within prior 12 months; pre‑treatment eGFR ≥25 mL/min/1.73 m2; prescribed by or in consultation with a cardiologist; patient on at least two standard HF medications from listed classes at appropriate doses.eGFR >=25 ml/min/1.73m2

    Authorization duration two years.

    Kerendia for CKD with T2DM: Tried an SGLT2 inhibitor or GLP‑1 RA initially with documentation supporting addition/switch (intolerance/contraindication) AND on maximally tolerated ACEI or ARB AND eGFR ≥25 mL/min/1.73 m2.eGFR >=25 ml/min/1.73m2

    Per-product coverage criteria (examples)

    Each listed product is subject to the following product-specific coverage criteria as stated below.

    General product entries: Products include exclusion criteria and criteria details such as required documentation, prescriber restrictions, coverage duration, and indication scope (often 'All Medically‑accepted Indications' or 'All FDA‑approved Indications').

    See individual product blocks for specifics.

    Examples of specific product criteria: Individual examples: Krazati must follow NCCN recommendations; Livtencity requires baseline CMV DNA and prior antiviral failure; Mekovi oral solution requires inability to swallow tablets; Mektovi requires BRAF V600 mutation documentation; Nexletol/Nexlizet require LDL‑C and prior statin/ezetimibe trials and must not be used with PCSK9 inhibitors; Nuedexta requires neurologist prescriber; Ofev requires HRCT confirmation and FVC criteria for certain ILD indications.

    This node represents multiple per‑product requirements across the index.

    Opipza — Covered with criteria

    Opipza (oral film) coverage conditions

    Opipza: Documentation supporting inability to use equivalent generic aripiprazole ODT and oral solution must be provided; coverage duration one year; indications: all medically‑accepted indications.

    Prescriber documentation required.

    Opsumit — Covered with criteria

    Opsumit (pulmonary arterial hypertension)

    Opsumit: Documentation that patient has pulmonary arterial hypertension (WHO Group 1) confirmed by right heart catheterization must be provided; coverage duration two years; indications: all medically‑accepted indications.

    Prescriber/diagnostic confirmation required.

    Orgovyx — Covered with prior therapy

    Orgovyx (prostate cancer hormone therapy)

    Orgovyx: Documentation of trial and failure (intolerance or inadequate response) with Firmagon (degarelix) is required; Part B prerequisite = yes; coverage duration one year.

    Prior degarelix trial documentation required.

    Pirfenidone — Imaging-confirmed diagnosis

    Pirfenidone (idiopathic pulmonary fibrosis and other indications)

    Pirfenidone: HRCT confirming diagnosis required for all indications; for IPF: diagnosis confirmed by surgical lung biopsy or UIP pattern on HRCT and other causes ruled out; prescriber is or has consulted a pulmonologist; reauthorization requires documented improvement; coverage two years.

    Diagnostic imaging required.

    Radicava — Initial and reauthorization criteria

    Radicava (edaravone) for ALS

    Radicava initial: Initial: diagnosis of definite or probable ALS per revised El Escorial/Arlie House criteria; diagnosis duration ≤2 years; baseline ALSFRS‑R total ≥24 (≥2 points on each of 12 items); percent‑predicted FVC ≥80%; coverage duration 12 months with volumetric dose limits; for reauthorization: documentation that Radicava is slowing progression compared to baseline.

    Missing required diagnostic/functional documentation may trigger denial.

    Repatha — Lab and prior statin therapy required

    Repatha (PCSK9 inhibitor) coverage conditions

    Repatha eligibility: Submit most recent LDL‑C and meet one of: (1) tried high‑intensity statin and LDL‑C remains above goal; OR (2) intolerant to high‑intensity statin and tried maximally tolerated statin with LDL‑C above goal; OR (3) tried two different statins and had statin‑related symptoms on both; coverage two years.LDL‑C per submission

    Prior statin/ezetimibe documentation required.

    Biologics with combination exclusions and prior therapy requirements

    Covered when ALL of the following are met

    Combination exclusion: Product is not used in combination with other biologic drugs, Otezla, or Janus Kinase Inhibitors (JAKis).
    Documentation of prior therapies and responses to treatment is provided.
    Prescriber is a specialist or has consulted with a specialist for the condition being treated.
    Dosing: Dose must be supported in FDA label or approved compendia where specified.

    Atopic dermatitis initial coverage

    Covered when ALL of the following are met

    Severity: Confirmation of moderate to severe atopic dermatitis.
    Topical therapy trial: Trial and failure (inadequate response) to one medium or higher potency topical steroid OR one topical calcineurin inhibitor.

    Sodium oxybate for narcolepsy

    Covered when ALL of the following are met

    Diagnostics: Documentation of MSLT and polysomnography confirming diagnosis of narcolepsy.
    Prior therapy: Trial and failure with a stimulant (amphetamine salts, dextroamphetamine or methylphenidate) AND trial and failure with modafinil or armodafinil.
    Prescriber must be a sleep specialist or neurologist.

    Rydapt for AML

    Covered when ALL of the following are met

    Mutation: Patient has FLT3 mutation‑positive disease as detected by an FDA‑approved test.
    Age: Patient is 18 years or older.
    Combination therapy: Used in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation chemotherapy for AML.

    Stelara and biosimilars

    Covered when ALL of the following are met

    Dose labeling: Dose must follow FDA‑approved labeling.
    Biosimilar trial: Documentation supports inability to use at least two preferred biosimilars (Yesintek, Selarsdi, ustekinumab‑AEKN) in place of Stelara.
    Prescriber is a specialist or has consulted with a specialist.

    Tolvaptan (hyponatremia and ADPKD)

    Covered when ALL of the following are met (separate branches for indications)

    Hyponatremia branch: (1) Documentation confirms hypervolemic or euvolemic hyponatremia with serum sodium <125 mEq/L OR symptomatic nonresponsive hyponatremia; AND (2) tolvaptan dosing up to 60 mg/day per FDA labeling.
    ADPKD branch: (1) Patient at risk of rapidly progressing ADPKD; AND (2) tolvaptan dosing up to 120 mg/day per FDA labeling.

    Tolvaptan - Indication-specific criteria

    Tolvaptan — Covered when ALL of the following are met for each indication

    Indication-specific: For hyponatremia: hypervolemic or euvolemic hyponatremia with serum sodium <125 mEq/L OR symptomatic nonresponsive to fluid restriction AND dosing up to 60 mg/day per FDA labeling. For ADPKD: patient at risk of rapidly progressing AND dosing up to 120 mg/day per FDA labeling.see text

    Coverage duration: hyponatremia 30 days; ADPKD 2 years.

    Tryngolza - Initial therapy criteria

    Tryngolza — Covered when ALL of the following are met

    Initial: (1) Diagnosis of familial chylomicronemia syndrome (FCS) confirmed; (2) fasting triglycerides >880 mg/dL; (3) refractory to statin, fibrate and omega‑3 ethyl ester therapy; (4) secondary causes excluded; (5) history of acute pancreatitis or recurrent abdominal pain.TG >880 mg/dL

    Initial duration one year; reauth two years with documented benefit.

    Voydeya - Initial and reauthorization

    Voydeya — Covered when ALL of the following are met

    Initial: (1) PNH diagnosis confirmed by flow cytometry; (2) actively receiving treatment with ravulizumab or eculizumab; (3) symptomatic extravascular hemolysis defined as fatigue or dyspnea AND (Hgb <9.5 g/dL OR absolute reticulocyte count >120 x10^9/L).Hgb <9.5 g/dL or ARC >120 x10^9/L

    Coverage duration one year initial and reauth; reauth requires improvement in EVH symptoms and hematologic markers.

    Vyndamax/Vyndaqel - ATTR-CM criteria

    Vyndamax/Vyndaqel — Covered when ALL of the following are met for ATTR‑CM initial coverage

    Initial ATTR‑CM: (1) NYHA class I–III heart failure; (2) ECHO or CMR demonstrating cardiac involvement (increased LV wall thickness); (3) diagnosis confirmed by tissue biopsy, genetic testing, or radionuclide imaging (99mTc‑PYP/DPD/HMDP); (4) if radionuclide imaging used, documentation of Grade 2 or 3 cardiac uptake.NYHA 1–3; radionuclide Grade 2–3 when applicable

    Not approved for primary light‑chain amyloidosis; initial and reauth one year; reauth requires positive clinical response vs baseline.

    Verquvo - HFrEF criteria

    Verquvo — Covered when ALL of the following are met

    Heart failure criteria: (1) Documentation of prior therapies and responses; (2) ejection fraction <45% within past 12 months; (3) symptomatic worsening chronic HF (NYHA II–IV) AND recent HF hospitalization within 6 months or outpatient IV diuretic in past 3 months; (4) tried and failed maximally tolerated combination: ACEI/ARB/ARNi AND bisoprolol/carvedilol/metoprolol ER AND spironolactone or other diuretic.EF <45%

    Must be prescribed by or in consultation with a cardiologist; age ≥18.

    Ustekinumab and biosimilars criteria

    Ustekinumab/Stelara and biosimilars — Covered when criteria met

    Stelara brand: (1) Documentation of prior therapies and responses; (2) dosing follows FDA label; (3) must document inability to use at least two preferred biosimilars (Yesintek, Selarsdi, ustekinumab‑AEKN) before approving Stelara.trial of ≥2 biosimilars unless contraindicated

    Prescriber should be specialist or consult one.

    Preferred biosimilars: For biosimilar products: documentation of prior therapies and responses; dosing per FDA label or supported compendia; for psoriasis must try and fail one traditional non‑biologic immunomodulator (e.g., methotrexate).trial of non‑biologic immunomodulator for psoriasis

    Coverage duration commonly two years.

    VIGAFYDE age restriction

    VIGAFYDE — Covered when ALL of the following are met

    Age‑limited coverage: Patient must be 2 years of age or younger (maximum age 2 years).age ≤2 years

    Coverage duration two years.

    VOWST criteria

    VOWST — Covered when ALL of the following are met

    Recurrent CDI: (1) Documentation of at least 2 recurrent episodes of CDI (3 or more total) after failure of appropriate antibiotic treatments; (2) patient age ≥18; (3) limited to one treatment course (12 capsules over 3 days).≥3 total CDI episodes with ≥2 recurrences

    Coverage duration one year.

    Winrevair PAH criteria

    Winrevair — Covered when ALL of the following are met

    PAH criteria: (1) Confirmed PAH (WHO Group 1) by right heart catheterization; (2) WHO functional class II or III; (3) tried and failed dual therapy with a PDE5 inhibitor and an endothelin receptor antagonist; (4) initiated as add‑on therapy to specified regimen.WHO FC II–III; diagnostic RHC confirmation

    Prescriber specialist; initial coverage one year; reauth two years with demonstrated benefit.

    Vyndaqel — Initial Therapy

    Initial coverage criteria for ATTR‑CM with Vyndaqel

    Vyndaqel initial ATTR‑CM criteria: (1) NYHA class I–III; AND (2) echocardiogram or CMR demonstrating cardiac involvement (increased LV wall thickness); AND (3) diagnosis confirmed by tissue biopsy, genetic testing, or radionuclide imaging (99mTc‑PYP/DPD/HMDP); AND (4) if radionuclide imaging used, documentation of Grade 2 or 3 cardiac uptake.

    Age ≥18; reauthorization requires documentation of positive clinical response vs baseline; not approved for light‑chain amyloidosis.

    Winrevair — Initial Therapy

    Initial coverage criteria for Winrevair (PAH)

    Winrevair initial PAH criteria: (1) Confirmed PAH WHO Group 1 by right heart catheterization; AND (2) WHO functional class II or III; AND (3) trial and failure of dual therapy with a PDE5 inhibitor and an endothelin receptor antagonist; AND (4) Winrevair initiated as add‑on therapy.

    Prescriber specialist; initial one year; reauth requires demonstrated beneficial response.

    Xolair — Indication-specific criteria

    Xolair coverage criteria by indication

    Asthma initial criteria: Baseline IgE ≥30 IU/mL AND baseline positive skin or in‑vitro reactivity to a perennial aeroallergen AND patient's current weight AND trial and failure of 1 ICS/LABA in past 6 months.IgE >=30 IU/mL

    Reauthorization requires clinical benefit and current weight/IgE; age and indication‑specific rules apply.

    Food allergy initial criteria: IgE‑mediated food allergy confirmed by positive in‑vitro IgE AND positive skin prick test AND clinical history of significant allergic reaction AND baseline IgE ≥30 IU/mL AND use with allergen‑avoidant diet AND patient's current weight AND age ≥1 year.IgE >=30 IU/mL; age >=1

    Reauthorization requires continued use with diet and documentation of benefit.

    Chronic urticaria initial criteria: Chronic urticaria >6 weeks AND trial and failure with one H1 antihistamine.>6 weeks

    Reauthorization requires documentation of clinical benefit.

    Nasal polyps initial criteria: Baseline IgE ≥30 IU/mL AND patient's current weight AND trial and failure with intranasal steroid AND continued intranasal steroid use with Xolair.IgE >=30 IU/mL

    Reauthorization requires benefit documentation and current weight/IgE.

    Yorvipath — Initial Therapy

    Yorvipath initial coverage for chronic hypoparathyroidism

    Yorvipath initial criteria: Confirmed chronic hypoparathyroidism duration ≥6 months with labs drawn together (PTH, calcium, magnesium, phosphate) AND provider attestation that condition is not adequately controlled on calcium and vitamin D (e.g., calcitriol).>=6 months

    Prescribed by or in consultation with an endocrinologist; not covered for acute postsurgical hypoparathyroidism or with other PTH analogs; reauth requires improved serum calcium.

    Xifaxan — Limits

    Xifaxan coverage limitations

    Xifaxan IBS‑D limits: For IBS‑D, no more than three total 14‑day treatment courses are covered; coverage for small intestinal bacterial overgrowth (SIBO) is not provided.<=3 courses

    Traveler's diarrhea limited to three days; trial of azithromycin required for TD in some cases.

    ACTHAR (repository corticotropin injection) is explicitly excluded from coverage for certain dermatologic and rheumatologic uses. Specifically, ACTHAR is not covered for acute gouty arthritis, severe psoriasis, and atopic dermatitis. For covered indications (other than infantile spasms), the policy requires a therapeutic trial of a parenteral glucocorticoid and Cortrophin with supporting documentation of prior therapies, and reauthorization requires demonstrated clinical benefit. Quantity and dosing must be consistent with the FDA‑approved label.

    Many biologic and targeted immunomodulator products are subject to combination‑use restrictions. The policy states that several agents must not be used in combination with other biologic drugs, Otezla, or Janus Kinase Inhibitors (JAKis); using these combinations is an exclusion that may trigger denial. Examples include COSENTYX, products described in the atopic dermatitis entries (which also require failure of Rinvoq and Dupixent), ENBREL, and other listed biologics. Otezla and RINVOQ are separately noted as not to be used with other biologics or JAK inhibitors. Documentation of prior therapies and prescriber specialty is also required when these combination exclusions apply.

    Amvuttra (vutrisiran) coverage for hereditary transthyretin-mediated (HATTR) polyneuropathy and ATTR‑CM includes a specific exclusion: Amvuttra will not be approved for primary (light‑chain) amyloidosis. Initial HATTR‑PN approval requires demonstration of a TTR mutation and baseline PND score ≤ IIIb; ATTR‑CM criteria require prior trial/intolerance to tafamidis and cardiac diagnostic confirmation per the policy.

    Colistimethate sodium administration by inhalation/nebulization is not covered. The policy requires that colistimethate be administered IV or IM with documentation that the infection is proven or strongly suspected to be caused by susceptible bacteria (culture/susceptibility or local epidemiology); nebulized/inhalation use is explicitly excluded because compendia do not support inhalation of colistimethate.

    Biologic agents carry explicit prohibitions on concurrent use with other biologic therapies or JAK inhibitors for the same condition. The policy consistently notes that many biologics must not be used in combination with other biologic drugs or JAK inhibitors, and that combination use may trigger denial. This combination prohibition is reiterated across multiple product entries (for example, Cosentyx, Enbrel and other listed biologics) and is accompanied by requirements for documentation of prior therapies and specialist prescriber involvement.

    General note on combination prohibitions: for multiple biologic and immunomodulator products the policy enforces a consistent rule—do not use these agents concurrently with other biologic drugs, Otezla, or JAK inhibitors. Where this prohibition applies, prior‑therapy documentation, specialist prescriber status, and dosing consistent with FDA labeling or supported compendia are required; failure to meet these requirements can result in denial.

    Coding, Laboratory Thresholds, and Numeric Criteria

    Listed drug namesNDC | text
    eltrombopagproduct name listed (eltrombopag olamine oral packet/tablet strengths 12.5 mg, 25 mg, 50 mg, 75 mg)
    Selected biologics and antiviralstext
    EMGALITYEmgality (300 mg dose) for migraine and cluster headache
    FASENRAFasenra (benralizumab) for severe eosinophilic asthma and EGPA
    EPCLUSAEpclusa oral tablet/packet for chronic hepatitis C
    Indexed drug and product entries (no billing codes in this section)mixed
    No codes listed
    inv-97: Eosinophil thresholds for Dupixent
    Dupixent eosinophil threshold (initiation)>= 150 cells/μl at therapy initiation
    Dupixent eosinophil threshold (historical)>= 300 cells/μl in the prior 12 months
    Indication contextThresholds applied for eosinophilic asthma indications as part of initial coverage criteria
    inv-98: Blood eosinophil count
    Blood eosinophil - near-term>= 150 cells/μl within 6 weeks prior to treatment
    Blood eosinophil - prior year>= 300 cells/μl in the previous 12 months
    UseRequired documentation for initial coverage of severe eosinophilic asthma
    inv-99: Eltrombopag ITP platelet count
    Platelet threshold (primary ITP)Platelet count < 30,000/mcL
    Platelet threshold (bleeding risk)Platelet count < 50,000/mcL with bleeding or bleeding risk factors
    Coverage contextRequired for initial eltrombopag requests along with prior therapy failures
    inv-100: Fecal calprotectin
    Fecal calprotectin> 120 (used in documentation for shortened-interval biologic dosing decisions)
    Context of useOne of the objective markers acceptable to support active Crohn's/UC when requesting shortened-interval dosing
    Documentation expectationProvided with symptoms/imaging and trough levels per policy rules
    inv-101: CRP (presumed units)
    CRP threshold>= 300 (policy uses this CRP cutpoint in shortened-interval biologic dosing documentation)
    Presumed unitsPolicy presents CRP as numeric threshold consistent with document context (use with other markers)
    ContextUsed alongside fecal calprotectin, symptoms, and imaging to justify dosing adjustments for biologics
    inv-102: GH stimulation test peak
    GH stimulation test peakPeak < 10 ng/mL
    Alternative supportive criterionPeak < 15 ng/mL when accompanied by low IGF-1/IGFBP-3
    ApplicationRequired for pediatric GH deficiency confirmation per policy
    inv-103: Kerendia pre-treatment eGFR
    Kerendia pre-treatment eGFR>= 25 ml/min/1.73 m2
    ContextRequired for initial Kerendia therapy in HF or CKD with T2DM per coverage criteria
    Prescriber notePrescribed by or in consultation with a cardiologist when indicated
    inv-104: FVC decline
    FVC decline threshold (progressive phenotype)>= 10% absolute decline in FVC
    Alternative threshold>= 5% decline in FVC with worsening respiratory symptoms OR worsening fibrosis on imaging
    UseApplied for chronic fibrosing ILD with progressive phenotype (Ofev) diagnostic criteria and reauthorization
    inv-105: LDL-C threshold
    LDL-C threshold for Nexletol/Nexlizet/Repatha pathways>= 70 mg/dL
    Required prior stepTry high-intensity statin (or maximally tolerated) + ezetimibe for >=4 weeks before escalation
    DocumentationMost recent LDL-C must be submitted with prior therapy evidence
    inv-106: Age for Rydapt in AML
    Minimum age for Rydapt (AML)>= 18 years
    Mutation requirementFLT3 mutation-positive disease by an FDA-approved test (documentation required)
    Combination useUsed in combination with standard cytarabine/daunorubicin induction and cytarabine consolidation per criteria
    inv-107: Age for Symdeko
    Minimum age for Symdeko>= 6 years
    Diagnostic requirementLaboratory confirmation of an ivacaftor‑responsive CFTR mutation required for related CFTR modulators
    Coverage durationTypically two years as listed for CFTR modulators
    inv-108: Age for Tavneos
    Minimum age for Tavneos>= 18 years
    Use contextTavneos must be used as add-on to standard therapy (e.g., cyclophosphamide, rituximab, steroids) and patient must not be on dialysis
    ReauthorizationRequires reduction in BVAS and steroid dose for reauth
    inv-109: Tolvaptan sodium threshold for hyponatremia
    Serum sodium threshold (hyponatremia)Serum sodium < 125 mEq/L OR symptomatic hyponatremia nonresponsive to fluid restriction
    Indication-specific dosingTolvaptan dosing limited to up to 60 mg/day for hyponatremia per FDA labeling
    DocumentationConfirm hypervolemic or euvolemic hyponatremia and symptomatology as required
    inv-110: Tryngolza triglyceride threshold
    Tryngolza fasting triglyceride thresholdFasting triglycerides > 880 mg/dL (10 mmol/L)
    Clinical contextRequired for diagnosis of familial chylomicronemia syndrome and initial authorization
    Prior therapy requirementMust be refractory to standard triglyceride-lowering therapies (statin, fibrate, omega-3)
    inv-111: Baseline IgE for Xolair
    Baseline IgE for Xolair>= 30 IU/mL
    ApplicationRequired for initial coverage of asthma, food allergy, nasal polyps and used in reauthorization documentation
    Additional requirementBaseline positive perennial aeroallergen test required for asthma indication
    inv-112: Xifaxan IBS-D treatment courses
    Xifaxan IBS-D course limitNo more than three 14-day treatment courses for IBS-D
    Traveler's diarrhea limitTraveler's diarrhea (TD) limited to three days per course
    SIBO coverageCoverage for SIBO is not provided per policy

    Prior Authorization, Documentation, and Denial Risks

    Prior Authorization

    General prior authorization requirements

    Prior authorization required for many specialty drugs listed below. Providers must submit specific diagnostic tests, prior therapy documentation, and specialty prescriber attestation where noted. Reauthorization often requires documentation of clinical benefit compared to baseline. Do not combine with excluded concomitant therapies (see individual entries).

    Prior Authorization

    Amvuttra specific prior auth

    Amvuttra: Do not use with TTR-lowering agents (e.g., Onpattro) or TTR stabilizers (e.g., tafamidis). For ATTR-CM require documentation of diagnosis (tissue biopsy, genetic testing, or radionuclide imaging) and cardiac imaging (ECHO/CMR) showing involvement; if radionuclide imaging used, provide Grade 2–3 uptake. Initial and reauth documentation requirements apply.

    • Do not combine with TTR stabilizers or TTR-lowering agents
    • ATTR-CM: biopsy/genetic or radionuclide imaging; ECHO/CMR required
    • If radionuclide imaging used, provide Grade 2 or 3 uptake
    Prior Authorization

    Arikayce prior auth

    Arikayce (MAC lung disease): For initial review submit sputum culture confirming Mycobacterium avium complex and documentation of failure to achieve negative cultures after ≥6 months of a multidrug background regimen. Prescriber must be or consult infectious disease/pulmonology. Initial approval 6 months; reauthorization 12 months with negative sputum culture within 30 days.

    • Sputum culture confirming MAC required for initial review
    • Documentation of ≥6 months multidrug therapy and failure to sterilize cultures
    • Prescribed by/consult with ID or pulmonologist
    • Initial approval: 6 months; Reauth: 12 months (requires negative sputum culture within 30 days)
    Prior Authorization

    Briviact prior authorization

    Briviact (brivaracetam): Requires documentation of trial and failure of generic levetiracetam and at least one other generic anticonvulsant. Provide records demonstrating inadequate seizure control. Coverage two years; initial prior therapy required.

    • Trial/failure with generic levetiracetam and ≥1 other generic anticonvulsant required
    • Documentation of inadequate seizure control must be submitted
    • Coverage duration: 2 years
    Prior Authorization

    Cobenfy prior authorization

    Cobenfy: Must have documentation of trial and failure with two generic atypical antipsychotics (≥28 days each). Prescriber must be or consult a specialist. Provide prior therapy documentation and responses.

    • Two generic atypical antipsychotics trial/failure (≥28 days each) required
    • Prescriber: specialist or consult recommended
    • Coverage duration: 2 years
    Prior Authorization

    Dihydroergotamine prior authorization

    Dihydroergotamine (nasal): Prior authorization requires documentation of trial and failure of one non-oral triptan (e.g., sumatriptan nasal or injection) and trial and failure of Nurtec ODT.

    • Trial/failure of one non-oral triptan required
    • Trial/failure of Nurtec ODT required
    • Coverage duration: 2 years
    Prior Authorization

    Dupixent prior authorization

    Dupixent: Initial coverage requires indication-specific documentation (e.g., atopic dermatitis: moderate–severe disease and trial/failure of medium+ potency topical steroid or topical calcineurin inhibitor). Chronic urticaria: diagnosis >6 weeks and trial/failure of one H1 antihistamine. Reauthorization requires documentation of clinical benefit compared to baseline.

    • AD: confirmation of moderate–severe disease and prior topical steroid/calcineurin inhibitor trial/failure
    • Chronic urticaria: urticaria >6 weeks and trial/failure of one H1 antihistamine
    • Dupixent reauth: demonstrate clinical benefit vs baseline (exacerbation reduction, symptom improvement, decreased steroid use)
    Prior Authorization

    Chronic urticaria prior authorization

    Chronic urticaria (general biologics): For agents treating chronic urticaria (e.g., Dupixent, Xolair) initial requests require confirmation of chronic urticaria (>6 weeks) and trial/failure of at least one H1 antihistamine. Reauthorization requires documentation of symptom improvement.

    • Chronic urticaria defined as urticaria >6 weeks
    • Trial/failure of ≥1 H1 antihistamine required before approval
    • Reauthorization: documentation of clinical benefit (improved symptoms)
    Prior Authorization

    Eltrombopag prior authorization

    Eltrombopag: Initial ITP requests require platelet count <30,000/µL or <50,000/µL with bleeding or bleeding risk, documentation of inadequate response or intolerance to steroids/IVIG, and inadequate response/intolerance to rituximab or splenectomy. Not covered to normalize platelet counts. Reauthorization requires current platelet count <400 x10^9/L and evidence of response.

    • Not covered for use to normalize platelet counts
    • ITP initial: platelet count thresholds and prior therapy failures required
    • Eltrombopag must not be used with other maintenance thrombopoietin receptor agonists
    • Reauthorization: current platelet count <400 x10^9/L and evidence of response
    Prior Authorization

    Fasenra prior authorization

    Fasenra: Initial coverage for severe eosinophilic asthma requires elevated eosinophils (≥150 cells/µL within 6 weeks or ≥300 cells/µL in past 12 months) and trial/failure of an ICS/LABA. Reauthorization requires documentation of clinical benefit (reduced exacerbations, symptom improvement, reduced oral steroid use). For EGPA and other indications follow specific documentation needs.

    • Eosinophil thresholds: ≥150 cells/µL (within 6 weeks) or ≥300 cells/µL (past 12 months)
    • Trial/failure of 1 ICS/LABA in past 6 months required
    • Reauthorization: documentation of clinical benefit vs baseline
    • Initial coverage: 1 year; reauth: 2 years
    Prior Authorization

    Enbrel prior authorization

    Enbrel: For rheumatoid arthritis and related indications, require trial/failure of one traditional non-biologic immunomodulator (e.g., methotrexate). For JIA, patient may start Enbrel concurrently with methotrexate/sulfasalazine/leflunomide or have aggressive disease per prescriber. Document prior therapies and responses. Do not use in combination with other biologics, Otezla, or JAK inhibitors.

    • Trial/failure of traditional non-biologic immunomodulator required for RA
    • JIA: concurrent initiation with specified DMARDs allowed or aggressive disease justification
    • Do not use in combination with other biologics, Otezla, or JAKis
    • Coverage duration: 2 years
    Prior Authorization

    Eucrisa prior authorization

    Eucrisa: Approve after trial and failure of a prescription-strength topical steroid; if steroid inappropriate, trial and failure of a generic topical calcineurin inhibitor is required. Documentation of prior topical therapy must be submitted.

    • Trial/failure of prescription-strength topical steroid required
    • If steroid not appropriate, trial/failure of topical calcineurin inhibitor required
    • Coverage duration: one year
    Prior Authorization

    Growth hormone: prior authorization requirements

    Growth hormone therapies: For children submit ≥1 year growth velocity data, GH stimulation test results showing deficiency, bone age, IGF-1/IGFBP3 when required; prescriber must be appropriate specialist. For adults, confirm GHD via stimulation testing or criteria listed (e.g., >=3 pituitary hormone deficiencies). Documentation of diagnostic testing and growth curves required.

    • Children: untreated growth velocity curve with ≥1 year data, GH stimulation tests <10 ng/mL or alternative criteria
    • Adults: GH-stimulation test or child-onset persistent GHD or documented pituitary disease + ≥3 pituitary hormone deficiencies and low IGF-1
    • Prescriber: endocrinologist (or specialist)
    Prior Authorization

    Nexletol prior authorization

    Nexletol / Nexlizet (bempedoic acid ± ezetimibe): Submit most recent LDL-C and documentation of prior therapies and responses. Patient must have tried high-intensity statin (or maximally tolerated statin) plus ezetimibe as indicated; if statin-intolerant, document intolerance to at least two statins.

    • Submit most recent LDL-C level
    • Document trial of high-intensity statin ± ezetimibe or maximally tolerated statin
    • If statin-intolerant, document trials of ≥2 statins with intolerance
    Prior Authorization

    Nuedexta prior authorization

    Nuedexta: Coverage requires diagnosis of pseudobulbar affect from an underlying neurologic condition (e.g., ALS, MS, stroke) and that a neurologist prescribes. Provide medical records supporting diagnosis.

    • Diagnosis of pseudobulbar affect and documentation of underlying neurologic condition required
    • Prescribed by a neurologist
    • Coverage duration: 2 years
    Prior Authorization

    Tryngolza prior auth

    Tryngolza (volanesorsen): Initial requests require dosing per FDA labeling and confirmation of familial chylomicronemia syndrome (fasting TG >880 mg/dL) refractory to standard triglyceride-lowering therapies and history of acute pancreatitis. For reauthorization provide biochemical response or reduction in pancreatitis episodes.

    • Confirm FCS: fasting triglycerides >880 mg/dL and refractory to standard therapy
    • Document history of acute pancreatitis or recurrent abdominal pain
    • Reauthorization: evidence of benefit (biochemical response, reduced pancreatitis)
    Prior Authorization

    VOWST prior auth

    VOWST (fecal microbiota product for recurrent C. difficile): Require documentation of at least 2 recurrent CDI episodes (3+ total) after failure of appropriate antibiotics. Limited to one treatment course; patient must be ≥18.

    • Documentation of ≥2 recurrent CDI episodes after appropriate antibiotic failure (≥3 total episodes)
    • Patient age ≥18 years
    • Limit: one treatment course (12 capsules over 3 days)
    Prior Authorization

    Vigabatrin prior auth

    Vigabatrin: For refractory complex partial seizures require documentation of trial/failure with at least two other generic anticonvulsants. Provide seizure control documentation.

    • Trial/failure of ≥2 other generic anticonvulsants required
    • Documentation of inadequate seizure control must be submitted
    • Coverage duration: 2 years
    Prior Authorization

    Vyndaqel (ATTR-CM) prior auth

    Vyndaqel / Vyndamax (tafamidis) for ATTR-CM: Initial coverage requires NYHA class 1–3 heart failure with current manifestations or prior HF hospitalization, echocardiogram or CMR showing increased LV wall thickness, and diagnosis confirmation by tissue biopsy, genetic testing, or radionuclide imaging (99mTc-PYP/DPD/HMDP). If radionuclide imaging used, provide Grade 2–3 uptake. Reauthorization requires documentation of positive clinical response versus baseline.

    • NYHA class 1–3 and clinical manifestations or prior HF hospitalization
    • ECHO or CMR showing cardiac involvement (increased LV wall thickness)
    • Diagnosis confirmed by biopsy, genetic testing, or radionuclide imaging
    • If radionuclide imaging used, provide Grade 2 or 3 uptake
    • Reauthorization: evidence of clinical benefit vs baseline
    Prior Authorization

    Winrevair (PAH) prior auth

    Winrevair (PAH): Initial requests require right heart catheterization–confirmed PAH (WHO Group 1), WHO functional class II–III, and prior trial/failure of dual therapy with a PDE5 inhibitor and an endothelin receptor antagonist. Must be prescribed by or consult a PAH specialist. Reauthorization requires documentation of beneficial response (improved WHO class, risk status, or 6MWD).

    • Right heart cath confirmation of PAH (WHO Group 1) required
    • WHO FC II–III required
    • Trial/failure of PDE5 inhibitor + endothelin receptor antagonist required prior to add-on
    • Prescriber: PAH specialist or consult recommended
    • Reauthorization: document improvement in WHO class, risk status, or 6MWD
    Denial Risk

    Combination therapy exclusions

    Combination and concurrent-use exclusions to watch for: many biologics and specialty agents are not covered when combined with other biologic drugs, Otezla, JAK inhibitors, PCSK9 inhibitors (for certain agents), ACE inhibitors (with some HAE therapies), TTR-lowering/stabilizing agents, or other named concurrent therapies. Verify drug-specific exclusions before prescribing.

    • Do not combine many biologics with other biologics, Otezla, or JAK inhibitors
    • Certain drugs exclude PCSK9 inhibitors or specific classes (check product notes)
    • HAE agents: concurrent ACE inhibitor or other HAE preventives may be exclusionary
    Prior Authorization

    Haegarda exclusion and documentation

    Haegarda: Not covered if used with an ACE inhibitor, with other HAE preventative therapies (e.g., Orladeyo, Takhyzro), or for acute attacks. Submit C4, C1-INH protein, and C1-INH function labs to confirm diagnosis. Reauthorization requires documentation of decreased attack frequency.

    • Not covered with ACE inhibitors or other preventative HAE therapies
    • Not for treatment of acute HAE attacks
    • Submit C4, C1-INH protein, and C1-INH function results to confirm diagnosis
    • Reauthorization: evidence of decreased frequency of attacks
    Prior Authorization

    Livtencity prior authorization and documentation

    Livtencity: Baseline CMV DNA required to confirm diagnosis. Must document trial and failure with ganciclovir, valganciclovir, cidofovir or foscarnet prior to approval. Do not coadminister with other CMV antivirals. For reauthorization provide documentation of virologic response (CMV DNA level).

    • Baseline CMV DNA level required
    • Trial/failure with other CMV antivirals required prior to approval
    • Do not use concomitantly with ganciclovir/valganciclovir/cidofovir/foscarnet
    • Reauthorization: provide CMV DNA response documentation
    Prior Authorization

    Repatha LDL-C and prior therapy documentation

    Repatha (PCSK9 inhibitor): Submit most recent LDL-C and document prior statin history. Patient must have tried a high-intensity statin (or maximally tolerated statin) and ezetimibe as appropriate; if statin-intolerant, document intolerance to ≥2 statins. Do not combine with Nexlizet/Nexletol per product restrictions.

    • Submit most recent LDL-C level
    • Document trial of high-intensity statin ± ezetimibe or maximally tolerated statin
    • If statin-intolerant, document trials of ≥2 statins with intolerance
    • Do not coadminister with Nexl zet/Nexletol where restricted
    Denial Risk

    Denial triggers for specific products

    Denial triggers and high-risk denial conditions: missing required diagnostic tests (e.g., right heart cath for PAH, biopsy/radionuclide imaging for ATTR-CM), absent prior therapy trials where required, lack of documented clinical benefit on reauthorization, excluded concurrent therapies, or failure to submit required labs (e.g., C4/C1-INH for HAE, CMV DNA for Livtencity).

    • Missing confirmatory diagnostics (right heart cath, biopsy, HRCT, ECHO/CMR, mutation testing) often triggers denial
    • Absent prior therapy trials or documentation of failure is a common denial reason
    • Reauth denials often occur without documented clinical benefit vs baseline
    • Use/exclusion conflicts (concurrent prohibited agents) can cause denials
    Note

    No explicit authorization or denial rule

    No explicit authorization/denial rule: Some index entries indicate no additional prior authorization beyond standard documentation. Always verify product-specific rows for explicit prerequisites, as absence of a rule in the index does not guarantee coverage without standard prior therapy or diagnostic documentation.

    • If no explicit PA rule is listed, standard prior therapy and diagnostic documentation expectations still apply
    • Check product-level criteria for required labs, prescriber specialty, or prior therapy
    Documentation Required

    Tumor/mutation diagnostic documentation requirements

    Required mutation and diagnostic documentation (examples): BRAFTOVI and Mekinist/MEKTOVI/related agents require BRAF V600 mutation documentation; IDHIFA requires IDH2 mutation documentation; FLT3 mutation required for certain AML agents. Provide genetic or test reports when indicated.

    • BRAF V600 mutation documentation for BRAFTOVI and related BRAF-targeted agents
    • IDH2 mutation documentation for IDHIFA
    • FLT3 mutation confirmation for FLT3-targeted AML agents
    Documentation Required

    Cosentyx and biosimilar documentation expectations

    Cosentyx and other biologics: Provide prior therapy documentation and responses (e.g., methotrexate, NSAIDs, topical or systemic agents) per indication-specific step requirements. For biosimilar substitution denials, document inability to use preferred biosimilars where required (e.g., Stelara biosimilars).

    • Cosentyx: prior therapy trials vary by indication (e.g., NSAID for ankylosing spondylitis; methotrexate for psoriasis)
    • If policy requires inability to use biosimilars, document rationale and trials of preferred biosimilars
    Documentation Required

    Dupixent documentation requirements

    Dupixent documentation (additional): For reauthorization across indications provide objective evidence of benefit compared to baseline (e.g., reduction in lesion count, fewer exacerbations, decreased steroid use). For eosinophilic esophagitis, provide biopsy results (≥15 eosinophils/HPF) and prior PPI/topical steroid trial documentation.

    • Reauth: objective measures of improvement vs baseline required
    • EoE: esophageal biopsy with ≥15 eosinophils/HPF and prior PPI/topical steroid trials
    Documentation Required

    Ebglyss documentation requirements

    Ebglyss documentation: Initial atopic dermatitis coverage requires confirmation of moderate–severe disease and trials of Rinvoq and Dupixent. Reauthorization requires positive clinical response and documentation if using an every-2-week maintenance schedule due to inadequate response to every-4-week dosing.

    • Initial: trial/failure of Rinvoq and Dupixent required for AD
    • Reauth: document clinical response and dosing frequency rationale
    Documentation Required

    Reauthorization: demonstrate clinical benefit

    Reauthorization clinical benefit: Many agents require demonstration of clinical benefit at reauthorization (examples: Dupixent, Fasenra, Livtencity, Winrevair, Vyndaqel/Vyndamax, Haegarda, Radicava). Providers should submit objective measures (labs, imaging, symptom scales, exacerbation counts) comparing on-treatment to baseline.

    • Prepare objective baseline and on-treatment data for reauth (labs, imaging, functional scores)
    • Examples: CMV DNA decline, decreased HAE attack frequency, improved 6MWD or WHO class for PAH, reduced exacerbations for asthma agents
    Documentation Required

    Fasenra initial coverage documentation

    Fasenra initial coverage documentation: submit eosinophil counts and prior ICS/LABA failure; for EGPA provide non-severe classification documentation. Ensure dosing and prescriber specialty are documented for benefit determination (Part B vs Part D as applicable).

    • Eosinophil counts (current or within specified window) required
    • Trial/failure of ICS/LABA documented
    • Reauth: clinical benefit vs baseline required
    Documentation Required

    Epclusa documentation expectations

    Epclusa: Provide documentation consistent with AASLD/IDSA guidance for hepatitis C; confirm chronic HCV infection and follow recommended duration of therapy. For pediatric pellets verify age limits.

    • Documentation must align with current AASLD/IDSA guidance
    • Confirm chronic HCV infection prior to approval
    • Pediatric pellet age restrictions apply (3–21 years for pellets)
    Documentation Required

    Evrysdi documentation

    Evrysdi: For spinal muscular atrophy submit genetic confirmation of diagnosis; prescriber should be a neurologist; reauthorization requires objective clinical response showing slowing of progression or functional benefit.

    • Genetic testing confirming SMA required
    • Prescriber: neurologist or consultation with neurologist required
    • Reauthorization: documentation of clinical benefit vs baseline
    Documentation Required

    Biologic prior therapy and shortened-interval documentation

    Biologic prior therapy and shortened-interval documentation: When shortened-interval biologic dosing is requested (e.g., adalimumab products), submit evidence such as two of: symptoms, active imaging, fecal calprotectin >120, CRP ≥300, inadequate trough levels, and initial response to therapy. Specialist prescriber documentation is required.

    • For shortened-interval dosing, provide objective evidence (≥2 of listed items)
    • Inadequate trough levels and initial response documentation required
    • Prescriber: specialist or documented specialist consultation
    Documentation Required

    IDH2 mutation documentation

    IDH2 mutation documentation: For IDHIFA provide molecular testing confirming IDH2 mutation prior to approval.

    • Submit molecular testing confirming IDH2 mutation
    Documentation Required

    Krazati – NCCN documentation

    Krazati: Provide documentation that use follows current NCCN recommendations where required.

    • Medical records supporting adherence to NCCN guidance must be provided
    Documentation Required

    Livtencity – baseline and response documentation

    Livtencity response documentation: For reauthorization submit CMV DNA level demonstrating virologic response compared to baseline.

    • Provide on-treatment CMV DNA level showing response for reauthorization
    Documentation Required

    Mektovi oral suspension – swallow inability documentation

    Mektovi oral suspension: Coverage requires inability to swallow tablet formulation; submit documentation supporting swallowing impairment.

    • Document inability to swallow tablet formulation to justify oral suspension
    Documentation Required

    Nuedexta – diagnosis and prescriber documentation

    Nuedexta: In addition to diagnosis, document prescriber specialty (neurologist) and records supporting pseudobulbar affect due to an underlying neurologic disorder.

    • Diagnosis of PBA and underlying neurologic condition required
    • Prescriber: neurologist
    Documentation Required

    Opipza: inability to use generics

    Opipza: Provide documentation that the patient cannot use generic aripiprazole ODT or oral solution in place of Opipza before approval.

    • Document inability to use generic aripiprazole ODT and oral solution
    Documentation Required

    Orgovyx prior therapy requirement

    Orgovyx: Prior trial and failure with degarelix (Firmagon) is required; submit documentation of prior therapy attempt.

    • Document trial/failure of degarelix (Firmagon) prior to Orgovyx approval
    Documentation Required

    Pirfenidone diagnostic imaging and reauth

    Pirfenidone: For IPF require HRCT or surgical lung biopsy confirmation (UIP pattern) and prescriber to rule out other causes. Reauthorization requires documentation of improvement or benefit compared to baseline.

    • HRCT demonstrating UIP pattern or surgical lung biopsy required for IPF
    • Prescriber must rule out other causes of interstitial lung disease
    • Reauth: document clinical improvement vs baseline
    Documentation Required

    Radicava: ALS documentation

    Radicava (edaravone): Initial ALS requests require diagnosis per revised El Escorial/Arlie House criteria, duration ≤2 years, preserved activities of daily living (ALSFRS-R baseline), and %FVC ≥80%. Reauthorization requires documentation that progression is slowed or stable compared to baseline.

    • Definite/probable ALS per El Escorial criteria and diagnosis ≤2 years
    • Baseline ALSFRS-R demonstrating retained ADLs and %FVC ≥80%
    • Reauthorization: evidence Radicava is slowing progression vs baseline
    Documentation Required

    FLT3 mutation documentation

    FLT3 mutation documentation: For FLT3-targeted agents (e.g., Rydapt combinations) submit FDA-approved test results confirming FLT3-positive AML where required.

    • Submit FLT3 mutation testing results (FDA-approved test) when indicated
    Documentation Required

    Tolvaptan indication documentation

    Tolvaptan: Indication-specific documentation required. For hyponatremia submit serum sodium and confirm hypervolemic/euvolemic etiology; for ADPKD document risk of rapid progression. Adhere to FDA dosing limits and duration guidance.

    • Hyponatremia: document serum sodium and etiology; follow FDA dosing (≤60 mg/day)
    • ADPKD: document risk of rapid progression and follow ADPKD dosing (≤120 mg/day)
    Documentation Required

    Voydeya documentation requirements

    Voydeya: Initial PNH requests require flow cytometry confirmation, active treatment with ravulizumab or eculizumab, and symptomatic extravascular hemolysis (fatigue or dyspnea with Hgb <9.5 g/dL or ARC >120×10^9/L). Reauthorization requires ongoing treatment with complement inhibitor and improvement in EVH symptoms and hemoglobin.

    • Flow cytometry confirmation of PNH required
    • Active treatment with ravulizumab or eculizumab prior to Voydeya
    • Symptomatic EVH criteria required (fatigue/dyspnea + Hgb <9.5 g/dL or ARC >120×10^9/L)
    Documentation Required

    Vyndamax/Vyndaqel documentation (ATTR-CM)

    Vyndamax/Vyndaqel documentation: See ATTR-CM requirements above (diagnostic imaging/biopsy/genetic confirmation, NYHA class, and reauth clinical benefit). Do not use with TTR-lowering agents.

    • ATTR-CM: ECHO/CMR, biopsy/genetic or radionuclide imaging (Grade 2–3 uptake if radionuclide)
    • NYHA class 1–3 required
    • Do not combine with TTR-lowering agents
    Documentation Required

    Winrevair (PAH) documentation

    Winrevair (PAH) documentation: Ensure right heart catheterization, WHO group/class documentation, prior dual therapy trial, specialist prescriber, and objective response measures for reauthorization (WHO class, risk status, 6MWD).

    • Right heart cath confirmation required
    • Document prior PDE5 + ERA therapy failure
    • Specialist prescriber required
    • Reauth: objective measures (WHO class, risk status, 6MWD)
    Documentation Required

    Xolair documentation

    Xolair: For asthma and food allergy indications submit baseline IgE (≥30 IU/mL), evidence of sensitization (skin test or in vitro), patient's weight, and trial/failure of required inhaled therapies. Reauthorization requires clinical benefit documentation and current weight and baseline IgE.

    • Baseline IgE ≥30 IU/mL and allergen sensitization required for asthma and food allergy indications
    • Provide patient's current weight
    • Trial/failure of ICS/LABA (asthma) or intranasal steroid (nasal polyps) as indicated
    • Reauth: clinical benefit documentation and updated weight/IgE
    Documentation Required

    Yorvipath documentation

    Yorvipath: Initial hypoparathyroidism coverage requires confirmation of chronic hypoparathyroidism (≥6 months) with labs drawn together (PTH, calcium, magnesium, phosphate) and provider attestation that calcium + vitamin D therapy is inadequate. Reauth requires documented improved serum calcium.

    • Confirm chronic hypoparathyroidism ≥6 months with concurrent labs (PTH, calcium, magnesium, phosphate)
    • Attest that calcium/vitamin D therapy is inadequate
    • Reauth: documented improved serum calcium
    Step Therapy

    Disease-specific step therapy and utilization limits

    Disease-specific step therapy highlights: Many agents require failure of preferred/step agents before biologic/specialty initiation — examples include AUVELITY, Caplyta, Otezla, RINVOQ, Trelstar, Xeljanz, Xifaxan limits for IBS-D and SIBO, and others. Providers must document prior trials (drugs, durations, and responses) per product specifics.

    • AUVELITY, Caplyta, and other CNS agents: required prior antidepressant/antipsychotic trials documented
    • Otezla/RINVOQ/Xeljanz: required step and combination restrictions; do not combine with biologics/JAKis where indicated
    • Xifaxan: utilization limits (IBS-D three 14-day courses) and SIBO not covered

    Step Therapy Requirements and Tables

    ScopeStep requirement
    Rheumatologic/immune indications (e.g., RA, psoriasis, ankylosing spondylitis, hidradenitis suppurativa, uveitis, JIA)
    Must try and fail one traditional non-biologic immunomodulator or appropriate first‑line agent (examples: methotrexate, leflunomide, hydroxychloroquine, sulfasalazine; NSAID for ankylosing spondylitis) unless starting concurrently with methotrexate or patient has aggressive disease
    ProductRequired prior trials
    AUVELITY
    Trial and failure of an SSRI or SNRI AND trial and failure of one atypical antidepressant (e.g., bupropion, mirtazapine); failure defined as inability to improve depressive symptoms after ≥4 weeks
    ProductRequired prior trials
    Caplyta
    Documented prior therapies per indication; for schizophrenia must have tried and failed two generic atypical antipsychotics (e.g., aripiprazole, ziprasidone, olanzapine, risperidone, quetiapine) as specified
    ProductRequired prior trials/documentation
    DRIZALMA / duloxetine-related products
    Document inability to use duloxetine (generic Cymbalta) AND trial and failure of one other generic antidepressant (failure = inability to improve the condition)
    IndicationStep requirement
    Atopic dermatitis (moderate to severe)
    Trial and failure of Rinvoq AND trial and failure of Dupixent (both required); prescriber is specialist or consulted specialist; combination with other biologics/JAKis not allowed
    ProductRequired prior trial
    Enbrel (including Enbrel Mini)
    Trial and failure of one traditional non‑biologic DMARD (e.g., methotrexate) for RA/psoriasis; for ankylosing spondylitis try and fail one NSAID; prescriber specialist or consultation required; must not be used with other biologics/Otezla/JAKis
    ScopeGeneral biologic step requirement
    Biologic immunomodulators for rheumatologic/immune indications
    Must try and fail one specified traditional non‑biologic immunomodulator or appropriate first‑line agent (examples provided by indication); documentation of prior therapies and responses required; prescriber specialist or consulted specialist
    ProductRequired prior trials
    Marplan
    Documentation of trial and failure with two generic antidepressants (SNRIs, SSRIs, mirtazapine, or bupropion) is required
    ProductRequired prior therapy
    Repatha (PCSK9 inhibitor)
    Submit most recent LDL‑C and documentation of trial with one high‑intensity statin (or maximally tolerated statin) plus ezetimibe for ≥4 weeks OR statin intolerance after two statins; LDL‑C threshold and prior therapy documentation required
    ProductPrescriber requirement
    Otezla
    Prescriber must be a specialist or have consulted a specialist; documentation of prior therapies and responses required; must not be used in combination with other biologic drugs or JAK inhibitors
    ProductPrescriber requirement
    RINVOQ
    Prescriber must be a specialist or have consulted a specialist; prior therapy documentation required; must not be used in combination with other biologic drugs, Otezla, or JAK inhibitors; specific prior medication trials vary by indication (e.g., methotrexate for RA)
    Therapy classRequired prior trials
    Atypical antipsychotics (brand/generic) prior to branded agents
    Must document trials and failure with two generics (aripiprazole, olanzapine, quetiapine, risperidone, ziprasidone, or lurasidone) for at least 28 days each before approval of certain specialty formulations
    ProductRequired prior therapies
    Teriparatide
    Documentation of prior osteoporosis therapy: trial and failure/intolerance to oral bisphosphonate (alendronate, risedronate, or ibandronate) AND zoledronic acid OR very high fracture risk (T‑score ≤‑3.0 or ≤‑2.5 with fragility fracture) as alternative criterion; prescriber endocrinologist
    AreaRequirement
    Various specialty products (antidepressants, etc.)
    Must document specified prior trials as listed per product (examples include two generic antidepressants, two generic antipsychotics, biosimilar attempts where applicable)
    Documentation typeExpectation
    Prior trials and clinical responses
    Providers must document prior drug trials including duration and clinical response (inadequate response, intolerance, or contraindication) to support approval or reauthorization
    ScenarioDocumentation required
    Stelara (ustekinumab) brand requests
    Must document attempts to use at least two preferred biosimilars (Yesintek, Selarsdi, ustekinumab‑AEKN) and inability to use them before approving brand Stelara
    IndicationStep therapy requirement
    Rheumatoid arthritis (RA)
    Trial and failure of one traditional non‑biologic immunomodulator (e.g., methotrexate, leflunomide, hydroxychloroquine, sulfasalazine) required prior to biologic/JAK therapy
    Ankylosing spondylitis / NRAS
    Trial and failure of one NSAID required prior to biologic therapy
    ConditionRequired prior therapy
    Traveler's diarrhea
    Trial and failure of azithromycin required for coverage of Xifaxan for travelers' diarrhea
    Hepatic encephalopathy
    Trial and failure of lactulose required prior to coverage

    Quantity Limits and Dosing Constraints

    inv-276: CORTROPHIN dosage support
    Dosage supportDosage as supported by the FDA-approved label
    ApplicationApplies to CORTROPHIN quantity limits and dosage expectations across indications
    ReauthorizationReauthorization requires demonstrated clinical benefit per general rules
    inv-277: EBGLYSS dosing cadence
    EBGLYSS initial dosing cadenceInitial limited to 4 doses the first month
    Maintenance dosing cadenceThen 2 doses each month thereafter (maintenance)
    Coverage duration noteInitial authorization 1 year limited dosing; reauth 2 years per policy
    inv-278: Ojemda oral suspension (reconstituted) — 1 box
    Ojemda oral suspension quantity1 box (limited to 1 box per 28 days)
    RequirementCoverage requires inability to swallow tablet formulation for oral suspension
    DurationCoverage duration typically one year per product entry
    inv-279: Radicava quantity cadence
    Radicava quantity (starter)70 mL first 28 days
    Radicava ongoing quantity50 mL every 28 days thereafter
    ContextVolume limits accompany Radicava initial and reauthorization criteria
    inv-280: Radicava duration limit (12 months)
    Radicava duration limitCoverage limited to 12 months total treatment
    Reauthorization expectationReauthorization requires documentation that Radicava is slowing ALS progression
    Volume limitsSpecific volumetric dose limits apply (see quantity cadence)
    inv-281: Relistor — 6 months limit
    Relistor duration limit6 months maximum coverage duration
    ContraindicationPatient must not have mechanical gastrointestinal obstruction
    Prior therapyMust try and fail lactulose prior to coverage
    inv-282: Prevymis (oral) — 200 days
    Prevymis (oral) duration200 days
    ApplicationQuantity limit applies per product entry for antiviral prophylaxis or treatment scenarios
    DocumentationFollow product-specific documentation requirements when requesting Prevymis
    inv-283: SCEMBLIX 20mg — 60 tabs/30 days
    SCEMBLIX 20 mg limit60 tablets per 30 days
    SCEMBLIX 40 mg limit240 tablets per 30 days (see related entry)
    Coverage noteTablet limits specified in SCEMBLIX product entry; prescriber/oncology documentation may be required
    inv-284: SCEMBLIX 40mg — 240 tabs/30 days
    SCEMBLIX 40 mg limit240 tablets per 30 days
    Related limit20 mg formulation limited to 60 tabs per 30 days
    Age/prescriberMust be prescribed by or in consultation with an oncologist/hematologist for certain indications
    inv-285: tolvaptan (hyponatremia) — up to 60 mg/day
    Tolvaptan (hyponatremia) max doseUp to 60 mg/day per FDA labeling
    DocumentationSerum sodium <125 mEq/L or symptomatic nonresponsive hyponatremia required for coverage
    DurationHyponatremia coverage typically 30 days per policy branch
    inv-286: tolvaptan (ADPKD) — up to 120 mg/day
    Tolvaptan (ADPKD) max doseUp to 120 mg/day per FDA labeling
    EligibilityPatient at risk of rapidly progressing ADPKD required
    DurationADPKD coverage duration listed as 2 years in policy
    inv-287: Tolvaptan combined limits summary
    Combined tolvaptan limitsHyponatremia: up to 60 mg/day; ADPKD: up to 120 mg/day (dosing per FDA label)
    Indication-specific documentationHyponatremia requires serum sodium <125 mEq/L or symptomatic nonresponse; ADPKD requires risk of rapid progression
    Coverage durationsHyponatremia: 30 days; ADPKD: 2 years
    inv-288: VOWST — 12 capsules over 3 days (1 treatment course)
    VOWST treatment course12 capsules over 3 days (one treatment course)
    LimitSingle treatment course for eligible recurrent CDI per policy
    Age requirementPatient must be 18 years or older
    inv-289: Xifaxan — No more than three 14-day courses for IBS-D; TD limited to three days
    Xifaxan IBS-D course limitNo more than three 14-day courses for IBS-D
    Traveler's diarrhea course limitTD limited to three days per course
    SIBO coverageCoverage for SIBO is not provided
    inv-290: Zurzvvae (Zurzuvae?) — limited to one treatment course per year
    Zurzvvae annual limitLimited to one treatment course per year
    ApplicationPolicy-level quantity limit for specified product (Zurzvvae/Zurzuvae entry)
    DurationReauthorization and benefit rules apply per product-specific criteria

    Site-of-Care and Prescriber Specialty Requirements

    Billing Rule

    Colistimethate site‑of‑care rule: IV/IM only in hospital outpatient

    For PA‑site rules: colistimethate is covered IV/IM in hospital outpatient only; nebulization is not covered and will be denied if billed as nebulized.

    • Ensure site‑of‑care matches administration route in request.
    Billing Rule

    Ofev: prescriber specialist or consult required

    For Ofev, include documentation that prescriber is or has consulted with a specialist in the treated condition (pulmonologist) when submitting prior authorization.

    • Attach specialist consultation or note in the request.
    Billing Rule

    Mifepristone: endocrinologist prescriber requirement

    Mifepristone requests must indicate the prescribing clinician is an endocrinologist; include prescriber specialty in the authorization submission.

    • Specialist prescriber requirement is mandatory for coverage.
    Billing Rule

    Teriparatide: endocrinologist prescriber and prior osteoporosis therapy documentation required

    Teriparatide must be prescribed by an endocrinologist (specialty oversight); include prescriber specialty and prior osteoporosis therapy documentation.

    • Document prior bisphosphonate/zoledronic acid or high fracture‑risk rationale per teriparatide criteria.
    Billing Rule

    Sodium oxybate: sleep specialist/neurologist prescriber and prior trials required

    Sodium oxybate must be prescribed by a sleep specialist or neurologist; include specialty in the request and prior stimulant/modafinil trial documentation.

    • Failure to document required prior trials may lead to denial.
    Billing Rule

    Verquvo: cardiologist prescriber/consult and EF documentation required

    Verquvo must be prescribed by or in consultation with a cardiologist; include cardiology consultation and EF documentation when requesting coverage.

    • Provide EF value within past 12 months and prior guideline‑directed HF therapy trials.
    Billing Rule

    Winrevair: PAH specialist prescriber or consult required

    Winrevair must be prescribed by or in consultation with a PAH specialist; include right heart catheterization and specialist documentation in the prior authorization.

    • RHC confirmation and prior dual therapy failure documentation are required.

    Biosimilar Substitution and Documentation

    Billing Rule

    Stelara biosimilar preference: document inability to use preferred biosimilars

    For Stelara, provide documentation supporting inability to use at least two preferred biosimilars (Yesintek, Selarsdi, ustekinumab‑AEKN) before requesting brand Stelara.

    • List biosimilars attempted and provide clinical rationale if trials were not feasible.
    Billing Rule

    Stelara (ustekinumab): require documentation of attempts with preferred biosimilars

    When requesting Stelara (ustekinumab) specifically, show attempts or documented reasons why at least two preferred biosimilars (Yesintek, Selarsdi, ustekinumab‑AEKN) cannot be used prior to approving Stelara.

    • Attach attempt records or contraindication/intolerance documentation for each biosimilar.

    Policy Background and Scope

    Background: this file provides product‑specific prior authorization and coverage rules for a broad set of pharmacy and specialty drugs for Priority Health Medicare. It defines required prior therapies, diagnostic confirmation, documentation expectations, prescriber specialty requirements, combination exclusions, and typical authorization durations (commonly one to two years). Requests lacking required prior‑therapy documentation, diagnostic labs/imaging, or that propose excluded combinations may be denied or deemed not medically necessary.

    Key Definitions and Clinical Thresholds

    inv-226: HATTR-PN PND score definition
    PND score requirement (Amvuttra)Baseline PND score less than or equal to IIIb
    DefinitionPND (polyneuropathy disability) stages neuropathy severity used for HATTR-PN initial coverage
    DocumentationMedical records must support PND score alongside TTR mutation and clinical signs
    inv-227: PAH confirmation definition
    PAH confirmation methodRight heart catheterization confirming pulmonary arterial hypertension (WHO Group 1)
    ApplicabilityRequired documentation for coverage of multiple PAH drugs (e.g., Opsumit, Winrevair)
    Coverage duration noteTypical coverage durations noted (e.g., two years) per product entries
    inv-228: Chronic urticaria definition
    Chronic urticaria definitionUrticaria occurring for more than 6 weeks
    Prior therapy requirementTrial and failure of at least one H1 antihistamine required for initial coverage
    ReauthorizationRequires documentation of clinical benefit compared to baseline
    inv-229: ITP eligibility platelet threshold
    ITP eligibility thresholdPlatelet count < 30,000/mcL OR < 50,000/mcL with bleeding/bleeding risk
    Prior therapyInadequate response/intolerance to steroids or IVIG and to rituximab or splenectomy required
    ExclusionUse to normalize platelet counts is not covered
    inv-230: GHD confirmatory testing (growth hormone deficiency)
    GHD confirmatory testing (children)Two GH stimulation tests with peak <10 ng/mL or peak <15 ng/mL plus low IGF-1/IGFBP-3
    Additional pediatric criteriaUntreated growth velocity <10th percentile for bone age over >=1 year; open growth plates; bone age >=1 year behind chronological age
    PrescriberMust be prescribed by endocrinologist, gastroenterologist, or nephrologist
    inv-231: Pseudobulbar affect (context for Nuedexta)
    PBA coverage contextPseudobulbar affect requires underlying neurological condition (e.g., ALS, MS, stroke) documented
    Prescriber requirementMust be prescribed by a neurologist per product entry for Nuedexta
    DocumentationMedical records supporting diagnosis required with request
    inv-232: FVC decline thresholds (context for Ofev)
    FVC decline thresholds (Ofev)>= 10% OR >= 5% with worsening respiratory symptoms OR worsening fibrosis on imaging
    ApplicationUsed for chronic fibrosing ILD with progressive phenotype criteria and reauthorization
    Diagnostic requirementHRCT confirming diagnosis required for all Ofev indications
    inv-233: Biosimilar substitution rationale for Stelara
    Biosimilar substitution rationale (Stelara)Must document inability to use at least two preferred biosimilars (Yesintek, Selarsdi, ustekinumab-AEKN) before approving Stelara
    PrescriberPrescriber is a specialist or has consulted with a specialist
    DoseDose must follow FDA-approved labeling

    Initial Therapy Criteria and Requirements

    Reauthorization and Continuation Criteria